A detailed history of Bank Of America Corp transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 2,427,225 shares of CHRS stock, worth $4.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,427,225
Previous 2,118,804 14.56%
Holding current value
$4.2 Million
Previous $7.06 Million 17.77%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$2.02 - $3.14 $623,010 - $968,441
308,421 Added 14.56%
2,427,225 $5.8 Million
Q4 2023

Feb 14, 2024

BUY
$1.59 - $3.85 $3.1 Million - $7.51 Million
1,949,629 Added 1152.43%
2,118,804 $7.06 Million
Q2 2023

Aug 14, 2023

SELL
$3.79 - $8.3 $1.51 Million - $3.31 Million
-398,199 Reduced 70.18%
169,175 $722,000
Q1 2023

May 12, 2023

BUY
$5.89 - $10.52 $1.09 Million - $1.95 Million
184,924 Added 48.35%
567,374 $3.88 Million
Q4 2022

Feb 10, 2023

BUY
$5.69 - $10.07 $633,695 - $1.12 Million
111,370 Added 41.08%
382,450 $3.03 Million
Q3 2022

Nov 14, 2022

BUY
$7.17 - $13.87 $419,029 - $810,590
58,442 Added 27.48%
271,080 $2.61 Million
Q2 2022

Aug 12, 2022

SELL
$5.86 - $13.23 $198,976 - $449,224
-33,955 Reduced 13.77%
212,638 $1.54 Million
Q1 2022

May 16, 2022

BUY
$10.92 - $16.41 $440,949 - $662,635
40,380 Added 19.58%
246,593 $3.18 Million
Q4 2021

Feb 08, 2022

SELL
$15.81 - $18.99 $893,802 - $1.07 Million
-56,534 Reduced 21.52%
206,213 $3.29 Million
Q3 2021

Nov 15, 2021

BUY
$12.68 - $17.79 $136,436 - $191,420
10,760 Added 4.27%
262,747 $4.22 Million
Q2 2021

Sep 13, 2021

BUY
$12.95 - $15.41 $3.26 Million - $3.88 Million
251,987 New
251,987 $3.49 Million

Others Institutions Holding CHRS

About Coherus BioSciences, Inc.


  • Ticker CHRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,724,600
  • Market Cap $134M
  • Description
  • Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...
More about CHRS
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.